Understanding gamma delta T cells: the overlooked heroes of the immune system

3D graphic showing several T cells
3D graphic showing several T cells
Logo

Understanding gamma delta T cells: the overlooked heroes of the immune system

Most people know T and B cells as key players in adaptive immunity, but gamma delta (γδ) T cells are a lesser-known yet crucial subset. They play a unique role in fighting infections, cancer, and controlling chronic inflammation.

In this blog post, we explore γδ T cells’ growing importance in immunity.

Read time: 5–10 minutes

This information is intended for biological researchers and should not be viewed as advice on medical treatments using gamma delta T cells.

Check out our blog and get up to speed on the latest breakthroughs in gamma delta T cell biology and immunotherapy

Content overview

Content

  • What are gamma delta T cells?
  • What gamma delta T cell markers are there?
  • How do gamma delta T cells work?
  • Gamma delta T cells and their function in diseases
  • How are gamma delta T cells used for therapy?
  • What new developments are there in gamma delta T–cell research?

What are gamma delta T cells?

T cells are generally classified by the structure of their T cell receptors (TCRs), which are molecules on their surface that recognize antigens and trigger immune responses. Most T cells have alpha beta (αβ) TCRs, but a small subset – less than 10% in the human body – carry a combination of gamma and delta chains TCRs. They are known as γδ T cells.

Despite their relatively small numbers, γδ T cells play a unique and versatile role in the immune system, functioning at the crossroads between innate and adaptive immunity. The difference between alpha beta and gamma delta T cells is that the former rely on recognizing specific antigens presented by major histocompatibility complex (MHC) molecules, whilst γδ T cells can recognize antigens directly, making them fast responders to a wide range of infections and cellular stress signals.

What gamma delta T cell markers are there?

To identify γδ T cells, certain surface markers are commonly used. These markers help distinguish γδ T cells from other T cells, and also indicate their functional state. In humans, there are three major γδ T cell subsets classified based on their T cell receptor delta variable (TRDV) genes expressed on the TCRδ (TRD) locus, which are referred to as Vδ1+, Vδ2+, and Vδ3+.1-4

Theoretically, recombination of the TCRδ (TRD) locus (TRDV, TRDD, TRDJ) and the TCRγ (TRG) locus (TRGV, TRGJ) could create a large diversity of TCR sequences. However, in reality, most of the peripheral Vδ2 T cells display semi-invariant TCR repertoires, using the same Vγ9 gene segments, which are the major γδ T cell subset in human blood (up to ~90% of circulating γδ T cells).5

Overview of the δTCR chain-based taxonomy of γδ T cells.

TypeVδ1 T cellsVδ2 T cellsVδ3 T cells
StructureVδ1-encoded TCRs and natural killer receptors (NKR).Two subgroups: 1) Vδ2-encoded TCRs and 2) NKR.Vδ3-encoded TCRs.
LocationReside in specific (mucosal) tissues, such as intestine and spleen, and in smaller numbers in the peripheral blood.The major circulating pool of γδ T cells, in particular Vγ9Vδ2 T cells, account for up to 90% of circulating γδ T cells in adults.Relatively rare, found in the liver and peripheral blood.
FunctionRespond to stress-induced antigens, including MHC-like proteins of the CD1 family, such as CD1c and CD1d, Annexin A2, and MHC class I chain-related protein A and B (MICA/B), which are mostly upregulated in transformed cells and virus-infected cells.Significantly expand in response to phosphor-antigens (e.g., IPP, HMB-PP), which are intermediates of the isoprenoid biosynthesis pathway in microbes and tumor cells.Less well-characterized; recognizes MR1, an MHC class I–related protein, and may recognize CD1 molecules involved in lipid antigen presentation.
RoleMucosal immunity .
Response to viral infections (e.g., CMV).
Anti-tumor activity.
Antimicrobial defense (e.g., against Mycobacterium tuberculosis).
Tumor surveillance.
Rapid cytokine production (e.g., IFN-γ, TNF-α)
MHC-independent activation.
Possibly involved in liver immunity and in responses to viruses like CMV and HIV.
MarkersPerforin+/Granzyme-B+, CD16+, CXCR1+, CCR2+, NKG2D⁺Perforin+/Granzyme-B+, CD27–, CD45RA–, CXCR3+, CCR1+, CCR2+, CCR5+, NKG2D⁺, CD16+CD16+, CD56+, CD161+

How do gamma delta T cells work?

Gamma delta T cells are often referred to as "innate-like" T cells because they do not require the same antigen presentation mechanisms as conventional T cells. They can recognize stress markers on infected or transformed cells and respond without needing prior exposure to a pathogen or tumor, giving them a unique ability to act quickly in response to danger.6

Here’s how gamma delta T cells function:

  • Direct antigen recognition: Unlike αβ T cells, which need antigens to be presented via MHC molecules, γδ T cells can recognize a broader range of antigens, including phospho-antigens (molecules produced by pathogens or stressed cells), and antigens expressed by cancer cells.7,8
  • Rapid response: γδ T cells respond much faster than conventional T cells because they don’t need to "wait" for antigen presentation. This makes them an important early defense, particularly in mucosal tissues like the gut, skin, and lungs, where infections often enter the body.
  • Cytotoxicity: Like other cytotoxic T cells and natural killer (NK) cells, γδ T cells can directly kill infected, stressed, or cancerous cells. They release perforin and granzymes, which induce apoptosis (cell death) in target cells.9
  • Cytokine production: γδ T cells secrete a variety of cytokines, including interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), which help regulate immune responses and recruit other immune cells to the site of infection or injury.10
  • Bridging innate and adaptive immunity: γδ T cells can act as a bridge between the innate and adaptive immune systems. While they function in a way similar to innate immune cells by responding rapidly and non-specifically, they also have the potential to exhibit adaptive immunity, with some evidence suggesting they can develop memory-like properties after exposure to certain antigens.11

Gamma delta T cells and their function in diseases

γδ T cells play diverse roles in both health and disease, including pathogen defense, tissue homeostasis, and the regulation of immune responses. They are implicated in both protective and pathogenic processes, mounting rapid responses against infections and supporting tissue repair, while their dysregulation can promote chronic inflammation.

Here’s a list of diseases where γδ T cells play a role and how they contribute:

1. Cancer

  • Role: γδ T cells have potent anti-tumor activity through cytotoxicity, cytokine production (e.g., IFN-γ, TNF-α), and antigen presentation. They recognize stress-induced ligands on tumor cells and mediate killing via perforin/granzyme and Fas/FasL pathways.12,13
  • Examples: Leukemia, lymphoma, melanoma, colorectal cancer, lung cancer, breast cancer.

2. Infectious diseases

  • Role: γδ T cells respond to microbial infections by recognizing phospho-antigens from bacteria and parasites, producing pro-inflammatory cytokines, and lysing infected cells.
  • Examples:
    • Tuberculosis (TB): γδ T cells recognize Mycobacterium tuberculosis antigens, promoting macrophage activation and granuloma formation.14 In particular, Vγ9Vδ2 T cells are activated rapidly after phospho-antigen stimulation, releasing TNFα and IFNγ.15
    • Malaria: Contribute to early immune responses by releasing IFN-γ and aiding parasite clearance.16
    • HIV: Initially protective by targeting infected cells, but their function may decline with disease progression as HIV infection disrupts the balance between Vδ1 T cells and Vδ2 T cells (increasing Vδ1 T cells and depleting Vδ2 T cells) and causes dysfunction among γδ T cells.17,18

3. Skin disorders

  • Role: 95% of the cells in the epidermis are keratinocytes, the other 5% cells are resident immune cells including Langerhans cells and γδ T cells. γδ T cells help maintain skin integrity but can also drive inflammation in dermatological diseases.
  • Examples:
    • Psoriasis: Dermal γδ T cells respond to IL-23 stimulation by producing IL-17A, a cytokine that promotes keratinocyte proliferation and inflammation. These cells exhibit memory-like properties, contributing to the recurrence of psoriatic lesions.19
    • Atopic dermatitis: Loss of protective γδ T cells, called dendritic epidermal T cells (DETCs), can mediate elevated levels of the Th2 cytokine IL-4, which induces apoptosis of these cells, compromising skin barrier integrity and immune defense.20

4. Transplantation and Graft-Versus-Host Disease (GVHD)

  • Transplantation: Unlike conventional αβ T cells, γδ cells generally show low alloreactivity, meaning they don't strongly attack donor tissues presented via classical MHC molecules. This makes them less likely to drive graft rejection and they can promote immune tolerance or drive inflammation in transplant settings.
  • GVHD: Studies suggest that γδ T cells may contribute to immune reconstitution without exacerbating GVHD. For instance, higher levels of γδ T cells post-transplantation have been associated with improved overall survival and reduced incidence of acute GVHD.21,22

Icon showing publications
Research highlight

Read more about how the γδ T cell separation kit contributed to investigating the role of γδ T cells in cholangiocarcinoma.

Human Vγ9Vδ2 T cell expansion and their cytotoxic responses against cholangiocarcinoma
Sawaisorn, P. et al. (2024) Sci Rep. 14(1):1291. | Read article

Icon showing a publication
Research highlight

Read more about how REAfinity® Antibodies, MACS® Technology for RNA isolation, and microarray analysis contribute to the characterization of human γδ T cell subsets to define shared and lineage-specific traits.

Deep characterization of human γδ T cell subsets defines shared and lineage-specific traits
Sanz, M. et al. (2023) Front Immunol. 14:1148988. | Read article

How are gamma delta T cells used for therapy?

Adoptive cell therapy (ACT) with γδ T cells is gaining attention because these cells can recognize and eliminate tumor cells without MHC restriction, making them ideal candidates for off-the-shelf, allogeneic treatments. Two main strategies are being investigated: non-engineered γδ T cell therapy, which relies on the natural tumor-recognition and cytotoxic functions of expanded γδ T cells, and engineered γδ T cell therapy, where genetic modifications such as CAR expression enhance tumor specificity and persistence. While both approaches exploit the innate advantages of γδ T cells, they differ in complexity, precision, and therapeutic potential.23,24

Side-by-side comparison non-engineered γδ T cell therapy and engineered γδ T cell therapy γδ T cell therapies.

 Non-engineered γδ T cell therapyEngineered γδ T cell therapy
At a glanceThis approach involves isolating γδ T cells from healthy donors, expanding them ex vivo, and infusing them into patients without genetic modification.This strategy involves genetically modifying γδ T cells to target specific tumor antigens, enhancing their specificity and cytotoxicity.

These include: CAR-γδ T cells – γδ T cells with chimeric antigen receptors (CARs) to target specific tumor antigens; TCR-engineered γδ T cells – modified TCRs to enhance or redirect tumor recognition; Armored γδ T cells – engineering to secrete cytokines, resist immunosuppression, or improve persistence.
Key featureBroad tumor recognition: Vγ9Vδ2 T cells in particular detect tumor-induced metabolic stress via phospho-antigens, enabling them to target a wide range of malignancies.

Off-the-shelf products: γδ T cells from healthy donors can be safely administered to other individuals without matching, thanks to their low risk of causing GVHD.
Enhanced specificity: Genetic engineering of γδ T cells improves their targeting precision.

Potential dual targeting: Engineered γδ T cells can combine MHC-independent innate-like recognition with CAR/TCR/armored-directed specificity, providing a two-layer targeting mechanism.
Clinical applicationsThis therapy is being investigated in early-phase clinical trials for various cancers, including leukemia, lymphoma, and solid tumors.Engineered CAR-γδ T cell therapies are under investigation for various cancers, including B-cell malignancies and solid tumors.

In summary, while both allogeneic non-engineered γδ T–cell therapy and engineered γδ T–cell therapy, such as CAR-γδ T cells, hold promise for cancer treatment, they differ in their approaches to targeting tumor cells. Non-engineered γδ T–cell therapy offers a simpler, broad-spectrum approach with a favorable safety profile, whereas engineered γδ T–cell therapy provides enhanced specificity and potency through genetic engineering. Ongoing research and clinical trials will further elucidate the optimal applications and efficacy of these therapies.24 Below you will find an overview of γδ T–cell therapies currently in clinical trials.

What new developments are there in gamma delta T–cell research?

As discussed in the previous sections, recent research has highlighted γδ T cells and their potent cytotoxic capabilities, tissue-homing properties, and therapeutic potential – particularly in cancer, infectious diseases, and autoimmune conditions. Advances in γδ T–cell biology, expansion techniques, and clinical applications are opening new avenues for immunotherapy and reshaping our understanding of immune regulation.

These developments underscore the growing interest in γδ T cells as a promising avenue for cancer treatment, with ongoing research aimed at harnessing their unique properties to improve patient outcomes.

Gamma delta T cell clinical trials and therapeutic developments

IN8bio, a clinical-stage biopharmaceutical company, has been at the forefront of gamma delta T–cell therapy development. They recently completed the treatment of the first cohort in a Phase 1 clinical trial using their γδ T–cell therapy, INB-200, for patients with newly diagnosed glioblastoma multiforme, an aggressive brain cancer. This trial combines standard chemotherapy with γδ T cells genetically engineered to resist the lymphodepleting effects of chemotherapy, aiming to enhance the immune response against glioblastoma while minimizing toxicity to healthy tissues.

Phase 1 trial of drug resistant immunotherapy: A first-in-class combination of MGMT-modified γδ t cells and temozolomide chemotherapy in newly diagnosed glioblastoma.
Nabors, LB. et al. (2021) J Clin Oncol. 39 (suppl 15; abstr 2057). | Read article

Additionally, IN8bio published a peer-reviewed article in Frontiers in Immunology detailing their novel approach to treating solid tumors like glioblastoma using γδ T cell–based adoptive cellular therapy. Their DeltEx Drug Resistance Immunotherapy (DRI) strategy leverages the innate immune functions of γδ T cells, which can recognize stress-associated ligands on tumor cells, potentially improving patient outcomes.

Adoptive cell therapy for high grade gliomas using simultaneous temozolomide and intracranial mgmt-modified γδ t cells following standard post-resection chemotherapy and radiotherapy: current strategy and future directions.
Nabors, LB. et al. (2024) Front Immunol. 15:1299044. | Read article

Comprehensive analyses and biomarker identification

A study published in Cell Reports Medicine conducted a comprehensive analysis of γδ T cells across 33 cancer types. Researchers utilized a novel computational algorithm to analyze the gamma delta T cell–receptor landscape across 11,000 tumors, providing an extensive database that tracks cancer progression and responses to various treatments, particularly immunotherapy. The findings suggest that the diversity and clonality of γδ T cells can significantly impact patient survival and treatment efficacy, highlighting their potential as clinical biomarkers and therapeutic targets in cancer treatment.

Pan-cancer γδ TCR analysis uncovers clonotype diversity and prognostic potential
Yu, X. et al. (2024) Cell Rep Med. 5(10):101764. | Read article